Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder (PCSMP-TLPD) is a provisional entity with uncertain malignant potential according to the latest revision of the WHO classification for lymphoid neoplasms. We conducted a systematic literature review of all previously reported cases of PCSMP-TLPD to highlight their typical and atypical features. The main features of PCSMP-TLPD and its possible clinicopathologic overlap with similar disorders are also discussed. It is hoped that this review will provide a useful outline of this condition and the most important differential diagnoses. Finally, we recommend a rigorous consensus among cutaneous lymphoma experts in drafting diagnostic criteria and the best case definition.
small*medium pleomorphic, cutaneous AND small*medium pleomorphic, skin lymphoproliferative AND small*medium). A MeSH search was also conducted using the following terms: ("Lymphoma, T-Cell, Cutaneous" AND "CD4-Positive T-Lymphocytes", "Skin Neoplasms" AND "CD4-Positive T-Lymphocytes, "Lymphoproliferative Disorders" AND "Skin" AND "CD4-Positive T-Lymphocytes"). Duplicates were removed from hits in all databases. Screening of all studies for relevance by title and abstract was performed with the help of two independent reviewers. The kappa statistic was used to determine percentage agreement between the two investigators with a 95 % confi dence interval. A full-text review was then conducted for relevant articles to confi rm eligibility. Finally, the references of each relevant article were checked for possible additional records ( Figure 1 ). Disagreements were resolved by discussion and consensus among the investigators.
Eligibility criteria and study selection: All relevant fulltext articles describing cases with PCSMP-TLPD were considered with no restrictions.
Exclusion criteria: Duplicate articles, irrelevant publications, conferences or meetings abstracts, review articles, book chapters and reports in non-English languages were excluded.
Data extraction: The following data were extracted: year of publication, authors, number of reported cases, age/ age range, gender, number of lesions, site of lesions, type of lesions, associated symptoms or systemic manifestations, immunohistochemistry results, TCR/Ig clonality, treatment and outcome. Any remarks or critiques regarding the study Figure 1 Search strategy.
were also added. All data were recorded in a data abstraction form.
Methodological quality and risk of bias assessment: Based on the lack of validated tools to assess the risk of bias in case reports and case series, many previous authors have modifi ed the Newcastle-Ottawa Scale (NOS) to make it more suitable for such uncontrolled studies [4] [5] [6] [7] . In the present work, we adopted the same concept by eliminating comparability and adjustment items from the original NOS since the included studies are of non-comparative design. However, items that focused on selection, representativeness of cases, and ascertainment of outcomes and exposure were retained for bias assessment by the two reviewers. This resulted in fi ve criteria in the form of questions with a binary response (yes/ no) as to whether the item was suggestive of bias or not. These questions were: 1: Did the patient(s) represent all the cases of the medical center? (The studies did not mention whether the reported patient(s) represented all the case(s) of the medical center and we assumed that the authors had reported all cases in their center). 2: Was the diagnosis made correctly? 3: Were other important diagnoses excluded? 4: Were all important data cited in the report? 5: Was the outcome correctly ascertained? The quality of the report was considered as good (low risk of bias) when all fi ve criteria were fulfi lled, moderate when four were fulfi lled and poor (high risk of bias) when three or fewer were fulfi lled [ 5 ] . Any disagreements on the risk of bias evaluation were resolved by discussion.
Limitations of the study: Lack of any funding sources to provide a scientifi c translation service for articles in languages other than English.
Statistical methods: Descriptive statistics were used to evaluate the number of articles, number of cases, age, sex, number of lesions, lesion sites and outcomes. Data were expressed as the mean ± standard deviation, median and range for quantitative variables, and the number and percentage of categorical variables. The kappa statistic was used to determine the percentage agreement between the two investigators with a 95 % confi dence interval.
Results
A total of 56 articles were included after applying the eligibility and exclusion criteria as listed in Figure 1 Table A summarizes the main characteristics of the included studies. The total number of reported cases is 529. However, 12 patients (9 males, 2 females and 1 patient with no gender listed) were excluded since they were associated with either mortality or disseminated lesions and were no longer covered by the diagnosis of PCSMP-TLPD (Table A) . This meant that only 517 cases matched the diagnosis of PCSMP-TLPD according to the most recent WHO classifi cation. Of these, 245 were males, 227 were females and gender data were not available for 45 cases. Twenty-seven cases came from single case reports. The remainder of the included studies involves from two or more patients up to a case series with 136 patients. The median age of patients was 53 years; the age range was 0.5 to 91 years. Clinically, 80.08 % of cases had a single or solitary lesion, mostly on the head and/or neck. Complete remission without recurrence was achieved in 51.64 % of patients while 0.96 % of patients experienced partial remission. Unfavorable outcomes including relapses and recurrences were reported in 4.26 % of cases, and 3.48 % of patients were stable with persistent lesions. Unfortunately, the outcome data were missing for 110 patients and 95 patients were lost to follow-up (Table 1 ). All patients survived the disease; patients with fatal outcomes should not be currently classifi ed as PCSMP-TLPD (Table 1 , Figure 2 ). We strongly believe that according to the updated WHO classifi cation, no patients who had disseminated disease, an aggressive course or who died should belong to this benign category, because their diagnosis should be true lymphoma in most cases, as highlighted in the remarks and critiques column of Table A . A monoclonal T cell receptor β and/or γ chain rearrangement was reported in 323 patients. The risk of bias in the studied articles was assessed as low in 50 %, moderate in 37.5 % and high in 12.5 % of all articles (Table 2 ) .
Discussion
Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder (PCSMP-TLPD) is a provisional entity with uncertain potential for malignancy according to the recently revised WHO classifi cation of lymphoid neoplasms [ 8 ] .
Clinical presentations
PCSMP-TLPD affects mainly older adults with a median age of 53 years [ 9, 10 ] . However, any age can be involved including children [ 11 ] and even infants [ 12 ] (Table A) . There is little gender predilection, as we found that 245 reported patients were males, 227 were females and in 45 cases the gender data were missing. PCSMP-TLPD usually presents with asymptomatic solitary violaceous or erythematous papules, plaques, nodules or tumors. The head and/or neck are the most frequently affected sites (Figure 3 ), but the trunk or extremities can also be involved. Multiple lesions, pain, itching or ulceration have occasionally been described [ 13 ] . The main characteristics of all previously reported cases of PCSMP-TLPD are summarized in Table A .
Atypical presentations
A few unusual clinical presentations have been reported such as acneiform [ 14 ] , alopecia [ 15 ] and leprosy-like disease [ 16 ] . Drug-induced PCSMP-TLPD has also been reported for the methotrexate-etanercept combination [ 17 ] , vemurafenib [ 18 ] , interleukin (IL)-2 therapy for metastatic melanoma [ 19 ] and standard triple-agent immunosuppressive therapy (cyclosporine, prednisolone, and azathioprine) following heart transplantation surgery [ 20 ] , although this is an extremely 
Associations
Boussault et al. reported a unique case of PCSMP-TLPD associated with annular elastolytic giant cell granuloma (AE-GCG). Bexarotene treatment resulted in recovery from AE-GCG with partial improvement of PCSMP-TLPD lesions [ 23 ] . This granulomatous proliferation could be an immunological reaction against the lymphocytes [ 24 ] as it was also reported in some cases of leukemia [ 25, 26 ] . Wawrzycki et al. described a case of PCSMP-TLPD associated with myelodysplastic syndrome that converted later into myelomonocytic leukemia. Viral infections, genetic susceptibility, abnormal early progenitor cells and/or stimulation of a B-cell clone by CD4+ T-helper cells may explain this association [ 2 ] . Furthermore, a child with a unique association of PCSMP-TLPD and erythema chronicum migrans showed complete remission with oral amoxicillin [ 27 ] . Finally, PCSMP-TLPD has also been associated with advanced melanoma (n = 2) [ 18, 19 ] , superinfection of an ulcerative lesion with zygomycosis (n = 1) [ 28 ] and rheumatoid arthritis (n = 1) [ 17 ] .
Ultrasound and color Doppler
Rodríguez-Lomb et al. described the ultrasound fi ndings in a case of PCSMP-TLPD as a non-encapsulated dermal nodule with heterogeneous content and ill-defi ned boundaries. Both the superfi cial and deep planes of the nodule were markedly hypoechoic with regard to the intervening plane, which showed some hypoechoic tracts. Color Doppler examination also showed prominent neovascularization within the nodule [ 29 ] . Although these fi ndings may help, they are not diagnostic. 
Dermatoscopy
Pileri et al. [ 30 ] recently described a common vascular pattern in three patients with PCSMP-TLPD, which included an orange-pink background with overlying short, fi ne, curvy or serpiginous blood vessels. This characteristic dermatoscopic pattern may raise suspicion and improve diagnostic accuracy.
Histopathology
By defi nition, the cellular infi ltrates in PCSMP-TLPD are composed mainly of small to medium-sized pleomorphic lymphocytes, and the percentage of any large atypical cells is less than 30 % [ 31 ] . Some plasma cells, eosinophils, and histiocytes may be present as well. The dermal infi ltrate may have a nodular or band-like distribution with a grenz zone separating it from the epidermis, but focal epidermotropism or extension to the subcutaneous fat may also occur ( Figure 3 ). Granulomatous [ 13, 32 ] , folliculotropic [ 15, 33 ] and neurolymphomatosis [ 16 ] patterns have been reported in some cases.
Immunohistochemistry
The offending T-cells in PCSMP-TLPD are always CD3+ & CD4+ and CD30- (Figure 3 ) . Furthermore, loss of pan-T Figure 3 Clinicopathological findings of PCSMP-TLPD. Well-defined solitary violaceous nodule affecting the left cheek (a). Dense diffuse dermal infiltrate of lymphocytes sparing the epidermis (hematoxylin-eosin stain [HE], original magnification x 4) (b). At higher magnification the infiltrate is composed of small to medium-sized pleomorphic lymphocytes surrounding eccrine structures (HE, x 400) (c). Diffuse CD 4+ staining for the infiltrating lymphocytes (DAB, x 4) (d). A higher magnification of (3d) showing diffuse CD4+ small to medium-sized pleomorphic lymphocytes surrounding eccrine structures (DAB, x 400) (e).
labelled cells is uncommon except for CD7- (Table A) ; some CD8+ cells and a few CD30+ immunoblasts may be found [ 13 ] . Remarkably, CD20+ B-cells are numerous and represent 10 %-60 % of the infi ltrate [ 34 ] . A low Ki-67 proliferation index was found in most cases [ 13 ] . Recently, some CD4+ T cells in PCSMP-TLPD have been found to co-express variable levels of programmed death 1(PD1), B-cell lymphoma 6 (BCL6), C-X-C motif chemokine ligand 13 (CXCL13), inducible co-stimulator (ICOS) and CD10. These markers may indicate that the offending cells in PCSMP-TLPD have a T-follicular helper (TFH) phenotype. TFH cells are required for B-cell proliferation and differentiation, which explains the infi ltrate of numerous B-cells in this condition [ 34, 35 ] . Regardless of the rich B-cell background, germinal centers were not reported with this condition. However, Davick et al. [ 19 ] recently detected focal germinal centers with CD10+ and BCL-6+ cells in one patient; this deserves larger studies. Enlarged CD4+ T cells that express PD1 may form "pseudo-rosettes", defi ned as PD1-positive cells distributed around a single large PD1 negative cell. The expression of at least three of the TFH markers was initially considered a criterion for the diagnosis of PCSMP-TLPD, but this criterion may also be satisfi ed in certain cutaneous lymphomas, reducing its diagnostic reliability [ 36 ] . However, Krenács et al. reported that such TFH cells specifi cally lack expression of the TFH-cell-defi ning chemokine receptor (CXCR5), which is a very characteristic fi nding for PCSMP-TLPD. This lymphoproliferative disorder is always negative for Epstein-Barr virus [ 37 ] . Calcineurin/nuclear factor of activated T-cells-c1 (NFATc1) was recently shown to produce signifi cant nuclear staining of lymphocytes (nuclear in neoplastic cells; cytoplasmic in both neoplastic and reactive cells) in PCSMP-TLPD, which would be helpful in differentiating it from MF (predominantly cytoplasmic in both neoplastic and reactive cells) and pseudolymphoma (almost exclusively cytoplasmic) [ 38 ] . However, larger studies are needed to confi rm this interesting fi nding.
Molecular studies
Array-based comparative genomic hybridization revealed no signifi cant genomic alterations in PCSMP-TLPD, which explains the indolent nature of this lymphoproliferative disorder [ 36 ] . However, clonal T cell receptor β and/or γ chain rearrangement has been detected in most cases [ 39 ] , around 331 of 436 patients tested (Table A) . Furthermore, Krenács et al. used microdissection to show that T-cell clonality is linked to PD1+ cells, suggesting that they are the cells of origin in PCSMP-TLPD [ 37 ] . Additionally, the clonality of Ig heavy and/or light chains has been tested in some patients, and was found to be mostly polyclonal [ 27, 34, 40 ] .
Differential diagnosis
The main differential diagnoses for PCSMP-TLPD are cutaneous lymphoid hyperplasia (CLH), tumor stage of mycosis fungoides (MF), primary cutaneous follicle center lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma (PCMZL), which are illustrated in Table  3 . PCSMP-TLPD should also be differentiated from nodal T-cell lymphomas with TFH phenotype as follicular T cell lymphoma (FTCL). Most patients with FTCL present with systemic lymphadenopathy. Extranodal involvement affects the skin in 23 % of cases, either at the time of diagnosis or at relapse in the form of erythema, papules or solitary skin lesions. In contrast to PCSMP-TLPD, FTCL is associated with frequent abnormalities of laboratory values (e.g. positive Coombs test and elevated serum lactate dehydrogenase level) as well as numerous genetic mutations [ 1, 41 ] .
Course and prognosis
The clinical course of PCSMP-TLPD is variable. Lesions may wax and wane over a course of weeks to years, or simply resolve spontaneously after a skin biopsy [ 42 ] . PCSMP-TLPD generally has a favorable prognosis and indolent behavior, with 5-year survival rates of 98.4 % among reported cases, especially with solitary lesions as shown in Table 1 and Figure 2 . Another minor group of patients whose outcomes are probably unfavorable may present with an aggressive course, multiple, large and rapidly growing, recurrent, treatment-resistant and fatal lesions [ 9 ] . It has been proposed that this should be reconsidered as peripheral T-cell lymphoma, unspecifi ed/NOS [ 9 ] . Histopathology showing a high proliferative index, low CD4 expression and infi ltrates lacking background infl ammatory cells including B-cells and CD8+ T cells have been associated with unfavorable outcomes [ 34 ] .
Treatment
The optimal treatment for PCSMP-TLPD has not yet been defi ned. However, various therapeutic options have been used for solitary lesions, including surgical excision, radiotherapy or a combination of both [ 28, 34, 40, 43 ] , as well as topical, intralesional or oral steroids [ 15, 42, 44 ] , doxycycline monohydrate [ 45 ] , amoxicillin [ 27 ] , cryocautery [ 37 ] and bexarotene [ 23 ] . Systemic chemotherapy (including cyclophosphamide either as monotherapy or in association [ 45 ] , multi-agent chemotherapy (as cyclophosphamide, hydroxydaunomycin, oncovin and prednisone (CHOP) therapy) [ 45 ] and systemic interferon-alfa [ 46 ] have been used for patients with multiple aggressive lesions, which are now considered mostly as true lymphomas rather than cases of PCSMP-TLPD.
Future prospects
No diagnostic criteria are currently available for PCSMP-TLPD; it is still a provisional entity with uncertain malignant potential, even in the recently revised WHO classifi cation. This justifi es the need to formulate a diagnostic tool that may help fi nally to determine the best case defi nition. We strongly believe that diagnosis of PCSMP-TLPD should be based on proper "clinical-histopathological-immunohistochemical-molecular" correlation, but rigorous consensus among experts is needed to determine the diagnostic criteria. This article summarizes the typical and atypical fi ndings that have been reported in literature with cases of PCSMP-TLPD ( Abbr.: PCSMP-TLPD: primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder; MF: mycosis fungoides; CLH: cutaneous lymphoid hyperplasia; pcFCL: primary cutaneous follicle center lymphoma; pcMZL: primary cutaneous marginal zone lymphoma; M: male; F: female; NM: not mentioned; TCR: T cell receptor; Ig: immunoglobulin; PD1: programed death 1; BCL6: B-cell lymphoma 6; BCL2: B cell lymphoma 2; CXCL13: C-X-C motif chemokine ligand 13; ICOS: inducible T-cell costimulator; CXCR5: C-X-C motif chemokine receptor 5; NFATc1: calcineurin/nuclear factor of activated T-cells-c1; +: positive; -: negative; +/-: positive or negative. but further studies are still needed to confi rm these fi ndings. We hope that this work will be useful for our colleagues.
Conclusion
PCSMP-TLPD is currently a provisional entity according to the recently revised WHO classifi cation of lymphoid neoplasms. We hope that the present work provides an up-to-date understanding of this condition and its important differential diagnoses. We encourage cutaneous lymphoma experts to develop a consensus on appropriate diagnostic criteria and the best case defi nition.
